Rilvegostomig Appears Safe, Effective for CPI-naïve Metastatic NSCLC

Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in checkpoint inhibitor (CPI)-naïve patients with metastatic non-small-cell lung cancer (NSCLC), according to a study presented at the 2024 IASLC World Conference on Lung Cancer.

In this open-label, global, multicenter study, researchers analyzed 95 patients who received rilvegostomig in Part C (PD-L1 Tumor Proportion Score [TPS] ≥1%) and Part D (PD-L1 TPS ≥50%). Rilvegostomig is an anti-PD-1/TIGIT bispecific antibody.

In Part C, all patients recieved 750 mg Q3W. In Part D, patients were randomized 1:1 to receive 750 mg or 1,500 mg Q3W. The primary endpoints included objective response rate (ORR) by RECIST v1.1 and safety by CTCAE v5. Key secondary endpoints included duration of response (DoR) and progression-free survival (PFS).

The findings showed that rilvegostomig was well tolerated; it also presented few treatment-related discontinuations (4.2%) and grade ≥3 treatment-related adverse events (10.5%). Moreover, the researchers observed no evident differences between 750 mg and 1500 mg in the safety profile.

“In CPI-naïve patients, rilvegostomig showed a favourable safety profile and encouraging preliminary efficacy in those with PD-L1 TPS 1‒49% and PD-L1 TPS ≥50%. Data support 750 mg Q3W as the pivotal dose for registrational studies,” the researchers concluded.

Reference

Hilterman TJN, Izumi H, Cho BC, et al. Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%. Abstract OA11.03. Presented at the IASLC World Conference on Lung Cancer; September 7-10, 2024; San Diego, California.